I‐SPY2 trial yields first results on combination therapy for triple‐negative breast cancer

E-ISSN： 1097-0142|120|6|773-773

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.6, 2014-03, pp. : 773-773

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Triple-negative breast cancer

By Bartsch Rupert

Wiener Medizinische Wochenschrift, Vol. 160, Iss. 7-8, 2010-04 ,pp. : 174-181

Springer Publishing Company

Access to resources Recommend Favorite

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer

Case Reports in Oncology, Vol. 5, Iss. 3, 2012-12 ,pp. : 687-692

Karger

Access to resources Recommend Favorite

First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study

Oncology, Vol. 82, Iss. 4, 2012-04 ,pp. : 218-227

Karger

Access to resources Recommend Favorite

A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-02 ,pp. : 112-118

Karger

Access to resources Recommend Favorite

The role of the androgen receptor in triple-negative breast cancer

By Shah Payal D Gucalp Ayca Traina Tiffany A

Women's Health, Vol. 9, Iss. 4, 2013-07 ,pp. : 351-360

Future Medicine

Access to resources Recommend Favorite